规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
靶点 |
hS1P1 ( EC50 = 27.3 pM ); hS1P5 ( EC50 = 334 pM )
|
---|---|
体外研究 (In Vitro) |
体外活性:Ceralifimod(也称为 ONO-4641)是一种新型 1-磷酸鞘氨醇 (S1P) 受体激动剂,对 S1P1 和 S1P5 具有选择性。虽然已经表明调节 S1P1 受体是治疗复发缓解型多发性硬化症 (RRMS) 等自身免疫性疾病的有效方法,但也有报道称 S1P3 受体的激活可能会产生一些不良反应。我们对亲水性头部区域带有氨基酸部分的命中化合物 6 进行了构效关系 (SAR) 研究。激酶测定:Ceralifimod(也称为 ONO-4641)是一种新型 1-磷酸鞘氨醇 (S1P) 受体激动剂,对 S1P1 和 S1P5 具有选择性。细胞测定:
|
体内研究 (In Vivo) |
Ceralifimod 用作临床候选药物,对 S1P1 的选择性比 S1P3 高 30 000 倍,并且在小鼠外周淋巴细胞降低 (PLL) 试验中有效(ED50 = 0.029 mg/kg,口服给药后 24 小时)。
|
酶活实验 |
Ceralifimod(也称为 ONO-4641)是一种新型选择性 1-磷酸鞘氨醇 (S1P) 受体激动剂,仅靶向 S1P1 和 S1P5。
|
动物实验 |
Rats: Inducer injections into the footpad at a volume of 0.1 mL are used to immunize female Lewis rats subcutaneously. Oral administration of ceralifimod (ONO-4641: 0.01, 0.03, and 0.1 mg/kg), prednisolone (3 mg/kg), or 0.5% MC is done once a day for immunization days 4 through 11. The clinical score is specifically determined by grading the degree of paralysis on a scoring scale.
Mouse: The inducer is injected into the left footpad of NOD mice at a volume of 0.05 mL. Forty-eight hours later, another PTX injection is given. Once every day for eight weeks, either 0.5% MC or Ceralifimod (ONO-4641: 0.01, 0.03, or 0.1 mg/kg) is given orally to each group of animals that achieve remission following the initial onset. The degree of paralysis determines how neurological symptoms are rated. Animals that are dead are given a clinical score of 5 until the end of the observation[1]. |
参考文献 |
分子式 |
C27H33NO4
|
|
---|---|---|
分子量 |
435.56
|
|
精确质量 |
435.24
|
|
CAS号 |
891859-12-4
|
|
相关CAS号 |
|
|
外观&性状 |
White to off-white solid powder
|
|
SMILES |
CCCC1=CC(=C(C=C1)COC2=CC3=C(C=C2)C(=C(CC3)CN4CC(C4)C(=O)O)C)OC
|
|
InChi Key |
QDDQIPUKAXBMBX-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C27H33NO4/c1-4-5-19-6-7-22(26(12-19)31-3)17-32-24-10-11-25-18(2)21(9-8-20(25)13-24)14-28-15-23(16-28)27(29)30/h6-7,10-13,23H,4-5,8-9,14-17H2,1-3H3,(H,29,30)
|
|
化学名 |
1-[[6-[(2-methoxy-4-propylphenyl)methoxy]-1-methyl-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylic acid
|
|
别名 |
|
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
|
|||
---|---|---|---|---|
溶解度 (体内) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 请根据您的实验动物和给药方式选择适当的溶解配方/方案: 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2959 mL | 11.4795 mL | 22.9589 mL | |
5 mM | 0.4592 mL | 2.2959 mL | 4.5918 mL | |
10 mM | 0.2296 mL | 1.1479 mL | 2.2959 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT01081782 | Completed | Drug: ONO-4641 Drug: ONO-4641 placebo |
Multiple Sclerosis | Ono Pharma USA Inc | March 2010 | Phase 2 |
NCT01226745 | Terminated | Drug: ONO-4641 | Multiple Sclerosis | EMD Serono | October 2010 | Phase 2 |
Female Lewis rats received a single oral dose of 0·5% methylcellulose (MC) (control) or ONO-4641 (0·1 mg/kg). Clin Exp Immunol . 2013 Jan;171(1):54-62. td> |
Time profile of clinical score in control and ONO-4641 groups. Clin Exp Immunol . 2013 Jan;171(1):54-62. td> |
Effect of ONO-4641 (0·01, 0·03 or 0·1 mg/kg) on number of peripheral blood lymphocytes in normal non-obese diabetic (NOD) mice 24 h after a single oral administration. Clin Exp Immunol . 2013 Jan;171(1):54-62. td> |